HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

voruciclib

a CDK4 and CDK6 inhibitor

Also Known As:

2-(2-chloro-4-(trifluoromethyl) phenyl)-5, 7-dihydroxy-8-((2R, 3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-1-benzopyran-4-one

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Buck, Steven A: 1 article (01/2020)
2.	Dzinic, Sijana H: 1 article (01/2020)
3.	Edwards, Holly: 1 article (01/2020)
4.	Ge, Yubin: 1 article (01/2020)
5.	Kushner, Juiwanna: 1 article (01/2020)
6.	Li, Xinyu: 1 article (01/2020)
7.	Lin, Hai: 1 article (01/2020)
8.	Luedtke, Daniel A: 1 article (01/2020)
9.	Ma, Jun: 1 article (01/2020)
10.	Polin, Lisa: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "Furthermore, voruciclib increased the intracellular accumulation and decreased the efflux of substrate anti-cancer drugs from ABCB1- or ABCG2-overexpressing cells. " 01/01/2018 - "Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells." 12/21/2017 - "When combined with venetoclax in vivo, voruciclib leads to model-dependent tumor cell apoptosis and tumor growth inhibition. "
2.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/21/2017 - "Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition."
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2020 - "Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia."

Related Drugs and Biologics

1.	venetoclax